PY2289204A - Pirrolo [2,1-f] [1,2,4] triazinas y preparación y usos de las mismas - Google Patents
Pirrolo [2,1-f] [1,2,4] triazinas y preparación y usos de las mismasInfo
- Publication number
- PY2289204A PY2289204A PY202202289204A PY2289204A PY2289204A PY 2289204 A PY2289204 A PY 2289204A PY 202202289204 A PY202202289204 A PY 202202289204A PY 2289204 A PY2289204 A PY 2289204A PY 2289204 A PY2289204 A PY 2289204A
- Authority
- PY
- Paraguay
- Prior art keywords
- pyrrolus
- triazines
- preparation
- pyrrolo
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163254733P | 2021-10-12 | 2021-10-12 | |
| US202263347757P | 2022-06-01 | 2022-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PY2289204A true PY2289204A (es) | 2023-12-05 |
Family
ID=84330173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PY202202289204A PY2289204A (es) | 2021-10-12 | 2022-10-12 | Pirrolo [2,1-f] [1,2,4] triazinas y preparación y usos de las mismas |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12134625B2 (enExample) |
| EP (1) | EP4415816B1 (enExample) |
| JP (1) | JP2024539620A (enExample) |
| KR (1) | KR20240089275A (enExample) |
| AU (1) | AU2022367222A1 (enExample) |
| CA (1) | CA3234831A1 (enExample) |
| IL (1) | IL312157A (enExample) |
| MX (1) | MX2024004552A (enExample) |
| PY (1) | PY2289204A (enExample) |
| TW (1) | TW202322800A (enExample) |
| UY (1) | UY39979A (enExample) |
| WO (1) | WO2023064366A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023212957A1 (en) * | 2022-01-25 | 2024-08-22 | Kinnate Biopharma Inc. | Inhibitors of cdk4/6 kinase |
| KR20250133646A (ko) * | 2022-11-03 | 2025-09-08 | 바이오스플라이스 테라퓨틱스, 인크. | 4-아미노피롤로[2,1-f][1,2,4]트라이아진 및 이의 제조 및 용도 |
| WO2024211797A1 (en) * | 2023-04-07 | 2024-10-10 | Biosplice Therapeutics, Inc. | Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof |
| CN119019402A (zh) * | 2023-05-24 | 2024-11-26 | 中国科学院上海有机化学研究所 | 作为lrrk2激酶抑制剂的多环化合物及其制备方法和用途 |
| AU2024298476A1 (en) * | 2023-07-26 | 2026-03-05 | Khora Spv 1, Llc | Inhibitors of cdk2/4/6 kinase |
| US20250206746A1 (en) * | 2023-12-22 | 2025-06-26 | Biosplice Therapeutics, Inc. | 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
| DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
| US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
| US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
| US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
| ES2364340T3 (es) | 2004-03-30 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | Azaindoles útiles como inhibidores de jak y otras proteína quinasas. |
| JP2008537684A (ja) | 2005-01-24 | 2008-09-25 | ニューロシステック コーポレイション | 内耳およびその他の組織へ治療薬および/またはその他の薬剤を送達するための装置および方法 |
| CA2728559A1 (en) | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
| WO2011018894A1 (en) | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
| US8362023B2 (en) * | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| ME03000B (me) | 2012-12-21 | 2018-10-20 | Plexxikon Inc | Jedinjenja i metode modulacije kinaze i povezane indikacije |
| WO2016010886A1 (en) | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| BR112017027951A2 (pt) * | 2015-06-22 | 2018-08-28 | Ono Pharmaceutical Co., Ltd. | composto inibitório de brk |
| AU2016315881B2 (en) * | 2015-09-03 | 2019-09-19 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK1A and uses thereof |
| FR3041640B1 (fr) | 2015-09-30 | 2019-05-17 | Les Laboratoires Servier | NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT |
| EP3694860A1 (en) * | 2017-10-10 | 2020-08-19 | Syros Pharmaceuticals, Inc. | Pyrrolotriazine compounds and methods of inhibiting tam kinases |
| CA3092828A1 (en) | 2018-03-01 | 2019-09-06 | The Trustees Of Columbia University In The City Of New York | Compounds, compositions, and methods for suppressing toxic endoplasmic reticulum stress |
| US12528810B2 (en) * | 2018-03-01 | 2026-01-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
| US20220062240A1 (en) | 2018-06-26 | 2022-03-03 | Biosplice Therapeutics, Inc. | Methods of treating cancer using a clk inhibitor |
| CN113015526A (zh) * | 2018-09-19 | 2021-06-22 | 豪夫迈·罗氏有限公司 | 螺环2,3-二氢-7-氮杂吲哚化合物及其用途 |
| JP7503054B2 (ja) | 2018-10-16 | 2024-06-19 | ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド | Lrrk2の野生型および変異型のアザインドール阻害剤 |
| EP3911317A2 (en) * | 2019-01-17 | 2021-11-24 | BioSplice Therapeutics, Inc. | Methods of treating cartilage disorders through inhibition of clk and dyrk |
| CN112094272A (zh) * | 2019-06-18 | 2020-12-18 | 北京睿熙生物科技有限公司 | Cdk激酶抑制剂 |
| WO2021257863A1 (en) * | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| CA3185649A1 (en) | 2020-07-20 | 2022-01-27 | Bakary-Barry Toure | Indole compounds as androgen receptor modulators |
| TW202330533A (zh) | 2021-10-12 | 2023-08-01 | 美商生物銜接醫療公司 | 7h-吡咯并[2,3-d]嘧啶及其製備及用途 |
| WO2023064349A1 (en) | 2021-10-12 | 2023-04-20 | Biosplice Therapeutics, Inc. | 1h-pyrrolo[2,3-b]pyridines as dyrk1a inhibitors |
| EP4543886A1 (en) | 2022-06-23 | 2025-04-30 | BioSplice Therapeutics, Inc. | 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof |
-
2022
- 2022-10-12 MX MX2024004552A patent/MX2024004552A/es unknown
- 2022-10-12 KR KR1020247014718A patent/KR20240089275A/ko active Pending
- 2022-10-12 WO PCT/US2022/046416 patent/WO2023064366A1/en not_active Ceased
- 2022-10-12 AU AU2022367222A patent/AU2022367222A1/en active Pending
- 2022-10-12 IL IL312157A patent/IL312157A/en unknown
- 2022-10-12 JP JP2024522052A patent/JP2024539620A/ja active Pending
- 2022-10-12 TW TW111138697A patent/TW202322800A/zh unknown
- 2022-10-12 UY UY0001039979A patent/UY39979A/es unknown
- 2022-10-12 EP EP22801289.4A patent/EP4415816B1/en active Active
- 2022-10-12 CA CA3234831A patent/CA3234831A1/en active Pending
- 2022-10-12 PY PY202202289204A patent/PY2289204A/es unknown
- 2022-10-12 US US17/964,489 patent/US12134625B2/en active Active
-
2024
- 2024-08-15 US US18/806,231 patent/US20250171466A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4415816B1 (en) | 2026-03-18 |
| MX2024004552A (es) | 2024-06-04 |
| WO2023064366A1 (en) | 2023-04-20 |
| CA3234831A1 (en) | 2023-04-20 |
| UY39979A (es) | 2023-04-14 |
| US20250171466A1 (en) | 2025-05-29 |
| TW202322800A (zh) | 2023-06-16 |
| IL312157A (en) | 2024-06-01 |
| US20230312605A1 (en) | 2023-10-05 |
| EP4415816A1 (en) | 2024-08-21 |
| JP2024539620A (ja) | 2024-10-29 |
| KR20240089275A (ko) | 2024-06-20 |
| US12134625B2 (en) | 2024-11-05 |
| AU2022367222A1 (en) | 2024-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39979A (es) | Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas | |
| UY39978A (es) | 7h-pirrolo[2,3-d]pirimidinas y preparación y usos de las mismas | |
| ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
| UY28084A1 (es) | Derivados antivirales de nucleosidos | |
| CO2022008243A2 (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos | |
| BR112017018022A2 (pt) | "compostos antivirais, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| MX2024015663A (es) | 4-alcoxipirrolo[2,1-f][1,2,4]triazinas y preparación y uso de las mismas | |
| SA98190487B1 (ar) | مركبات ثلاثي 3.2.1- ازولو ]4،5- D [ بيريميدين1,2,3-triazolo[4,5-D] pyrimidines حديثه واستخداماتها كعقاقير وطرق لتحضيرها | |
| MX2021003241A (es) | Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo. | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| BR9812048A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos de tratar uma doença mediada por uma cinase, de tratar a rejeição no transplante de órgão, e de tratar a alopecia induzida pela quimioterapia | |
| ECSP066730A (es) | Compuestos y procedimientos para uso | |
| CU24519B1 (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
| CO6300934A2 (es) | Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas | |
| BR0312398A (pt) | Derivado de 1,3-difenilprop-2-en-1-ona substituìdo, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituìdo | |
| ECSP034811A (es) | Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6 | |
| CL2021001209A1 (es) | Constructos de suministro para transcitosis y métodos relacionados | |
| BR112022003719A2 (pt) | Métodos para o tratamento de hiperfenilalaninemia | |
| EA202092002A1 (ru) | 5-гетероарилзамещенные индазол-3-карбоксамиды и их получение и применение | |
| MX2025005198A (es) | 4-aminopirrolo[2,1-f][1,2,4]triazinas y preparacion y usos de estas | |
| BR112022010181A2 (pt) | Composto tri-heterocíclico como inibidor de jak e uso do mesmo | |
| UY29899A1 (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos | |
| AR057239A1 (es) | Inmunoglobulinas | |
| CO2022011183A2 (es) | Conjugados de proteínas-compuestos antivirales | |
| MX2024002886A (es) | Metodos para tratar enfermedades neurodegenerativas. |